Cite
HARVARD Citation
Tess, D. et al. (2022). Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Clinical pharmacology & therapeutics. 112 (3), pp. 605-614. [Online].